Our survey found that 87% of biosimilar products were associated with patient copay assistance programs that cut out-of-pocket costs to $5 or less. Physician perceptions of important financial assistance differences between biosimilars and reference products seem generally unfounded. The newly published edition of the Samsung Bioepis Biosimilar Market Report indicates that with few exceptions, biosimilar … Continue reading Are Biosimilar Patient Copay Assistance Programs Lacking?